Brazil now has more than 873,000 medical cannabis patients, a market approaching $200 million in annual revenue, and a regulatory framework that just opened the door to domestic hemp cultivation. The industry gathers at Cannabis Fair 2026 in São Paulo from May 21 to 23. Here’s what US operators need to know about the Latin American market they aren’t tracking.
While most of the US cannabis industry is watching its own federal rescheduling drama and the November hemp THC cliff, the largest cannabis market in Latin America is quietly hitting the kind of patient and revenue numbers that took Germany years to reach.
Brazil’s medical cannabis market generated nearly R$953 million (roughly US$187 million) in 2025, according to the latest data from cannabis consultancy Kaya Mind. The country surpassed 873,000 registered medical patients as of November 2025, a number that puts it in the same territory as Germany, which has between 700,000 and 900,000 medical cannabis patients. Brazil has 221 million residents. Germany has 83 million.
The growth is steep. Patient numbers jumped 56% from 2023 to 2024. Revenue grew 22% in the same period. ANVISA, Brazil’s national health regulator, has now registered 49 medical cannabis products. More than 2,180 cannabis-based products are available across the country, and patients in 80% of Brazil’s 5,570 municipalities can now access them.
Brazil’s medical cannabis market
873K+
Registered medical cannabis patients (Nov 2025)
$187M
2025 medical market revenue (R$953M)
56%
Patient growth, 2023 to 2024
2,180+
Cannabis-based products available nationwide
Sources: Kaya Mind 2025 Yearbook, ANVISA, Brazilian Ministry of Health.
The cultivation door just opened
The biggest near-term shift in Brazil’s cannabis economy isn’t the patient growth. It’s a regulatory change that hit in November 2024 and is still working its way through the supply chain.
Brazil’s Superior Court of Justice authorized the import of seeds and cultivation of industrial hemp for medical and pharmaceutical applications. For an industry …
Read More
Author: Javier Hasse / High Times
